Open Door Salon

How Health Systems Decide Which AI to Buy | Paul Uhrig & Eddie Qureshi

Paul Uhrig is a healthcare lawyer and digital health executive, formerly Chief Legal and Digital Health Officer at Bassett Healthcare Network and Chief Administrative, Le

What Cell and Gene Therapy Investors Need to See First | Phil Vanek & David Crean

Phil Vanek, PhD, is Chief Commercialization Officer of the International Society for Cell & Gene Therapy (ISCT), chair of the CGT Catapult Technology Advisory Board and f

Is Your Biotech a National Security Target? | Chad Raduege

Retired Air Force Brigadier General Chad Raduege spent 29 years in communications, IT and cyber operations, commanded the White House Communications Agency, and finished

Why Digital Twins Won't Replace Patients | Nindhana Paranthaman & Paul Agapow

AI arrived in drug development carrying a very large promise. Nindhana Paranthaman, Vice President of Early Clinical Development at Bicara Therapeutics, and Paul Agapow,

What Gets a Biotech Pitch Funded: Mike Goguen and Christian Schubert

Six hundred investable opportunities in a year. Five investments. Christian Schubert, Vice President and Global Head of AbbVie Ventures, walks Lori Ellis through where th

Pivot or Close: What the Last 90 Days of a Biotech Wind-Down Look Like

David Esposito has built biotechs to exit and taken biotechs into bankruptcy. Pavel Khrimian spent most of 2026 winding down the company he co-founded, after a pharma col

What Happens When AI Gets Drug Discovery Wrong | Ryan Cawood & Raphaël Ognar

An AI fabricated a scientific citation. When Raphaël Ognar pushed back, it apologized, saying it had not wanted to fall short by giving him an unsatisfactory answer. He t

Where Biotech Money Goes When Venture Capital Stops | Sara Jane Demy & Jeremy Levin

The A, B, C round path that funded biotech for thirty years is not currently available. Sara Jane Demy has just come out of her own Biotech CEO Summit, where that was the

Why Alzheimer's Startups Still Struggle to Raise Money | Karen Harris & Mahesh Narayanan

Alzheimer's science is finally moving. Two disease-modifying drugs are approved. Two blood tests are approved. Biogen has taken an anti-tau drug into Phase 3. And early-

Healthcare's Biggest Problem Nobody's Talking About

Most biotech CEOs assume nation-state hackers are a big-pharma problem. Raja Mikkili and Anne Elise Herold Li explain why the opposite is true: the small and mid-size com

Former FDA Commissioner Robert Califf on RFK Jr., the FDA Exodus, and China

Robert Califf is the only person to have served twice as Commissioner of the FDA. Vid Desai was the agency's first Chief Information Officer to report directly to the Com

Why Patients Walk Away From a Cure They Qualify For | ISCT's Grilley & Boelens

Learn more about ISCT: https://www.isctglobal.org/home The science works. Cell and gene therapies are curing diseases that had no answer. So why can't patients get them?

The Three Forces That Make or Break a Launch: FDA, Payers & Hackers

This episode is made possible by MedTech World: https://med-tech.world/ Medtech launches don't fail for one reason. They fail at the FDA, at the payer, or at the firewal

Anna Titkova & Prashant Yadav: When War Stops a Patient's Treatment

Two wars, a pandemic threat, and a regulatory system under strain are hitting global health at the same time. Anna Titkova, who led clinical operations in Ukraine through

Theresa Campobasso: The Regulatory Wave Reshaping China Biotech Deals

New US rules are reshaping how pharma and biotech can do deals with China, and BIOSECURE was only the start. Theresa Campobasso, Senior Vice President at Aardwolf Global

China in Your Pharma Supply Chain: What BIOSECURE Misses

China is on everyone's mind in life sciences, and the pharma supply-chain risk runs deeper than the BIOSECURE Act reaches. Theresa Campobasso, a former U.S. Marine Corps

"Why Is CVS Selling Party Packs of M&Ms Alongside Ozempic?" | Pashazadeh & Rees

We have to apologize for the video quality. Ali's recording corrupted. GLP-1s hit $13 billion in sales last quarter — the highest-selling drug class globally. But a sur

"There's a 15 Minute Window on a Certain Tuesday" | Why Your Biotech Can't Get Funded

"There's probably about a 15 minute window on a certain Tuesday where you fit into the right window for an investor. You're too early. You're too late." Edwin Stone is t

"AI Won't Cut Corners" — A Hospital CIO and Community Advocate on the Digital Divide | McWilliams & Hicks

"AI is going to augment — it's going to allow things to work quicker, more efficiently. But it's not going to cut corners. It's not going to allow us to not do what's req

A Former CIA Chief & Supply Chain CEO on Why Iran Just Broke Your Pharma Supply Chain | Clinton West & Mike Walker

"When you start to peel back the onion of what Iran provides to us, healthcare is at the very top." A former CIA Chief and a former Microsoft VP on what the Iran war re